Celltrion applied to the FDA for a license to sell 'Lamsima' which is the world's first antibody biosimilar

On August 11, Celltrion announced that they applied to the FDA for a license to sell 'Remsima' which is the world's first antibody biosimilar on 8th last month.

This is the first time the United States permit the application of biotechnology to the antibody biosimilar, and it was the second case to apply for authorization established by the United States for the first time this BPCIA (Bio-Phar...